Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan
Mini Review
Alterations in Eosinophil Cationic Protein in Asthma and CRSwNP Participants Receiving Dupilumab
Author(s): Matsumoto Yasushi*
Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are chronic inflammatory diseases that affect the respiratory and nasal passages,
respectively. Both conditions are often characterized by elevated levels of eosinophil, a type of white blood cell that plays a crucial role in the
immune response. Eosinophilic inflammation is a key feature of these diseases and is associated with a range of symptoms and complications.
Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, inhibiting the signaling of both interleukin-4 (IL-4) and
interleukin-13 (IL-13). Dupilumab has demonstrated remarkable efficacy in treating asthma and CRSwNP, significantly reducing symptoms and
improving the quality of life for many patients. This success can be attributed to its ability to reduce eosinophilic inflammation, which leads to
alteratio.. Read More»
DOI:
10.37421/2952-8100.2023.6.438
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 